Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors

Kimberly J. Briggs(Io Therapeutics (United States)), Adam Crystal(C4 Therapeutics (United States)), Steven A. Lombardo(Io Therapeutics (United States)), David R. Spigel(Sarah Cannon), Kevin M. Cottrell(Io Therapeutics (United States)), Jennifer Morawiak(Io Therapeutics (United States)), Capucine Baldini(Centre National de la Recherche Scientifique), Ignacio Garrido‐Laguna(University of Utah), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Angela C. Hirbe(Washington University in St. Louis), Ibiayi Dagogo‐Jack(Massachusetts General Hospital), Heather DiBenedetto(Io Therapeutics (United States)), Douglas A. Whittington(Amgen (United States)), Yi Yu(Novartis (United States)), Alexander I. Spira(Virginia Cancer Specialists), Satoshi Yoda(Harvard University), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Andre Mignault(Novartis (United States)), Shangtao Liu(Tango Therapeutics (United States)), Ellen Hooper(Io Therapeutics (United States)), Hongxiang Zhang(Tango Therapeutics (United States)), Binzhang Shen(Tango Therapeutics (United States)), Samuel R. Meier, Hannah Stowe(Massachusetts General Hospital), Minjie Zhang(Xian Yang Central Hospital), Wenhai Zhang(Tango Therapeutics (United States)), Víctor Moreno(Peter MacCallum Cancer Centre), Teng Teng(Wuhan University), Heidi Rego(Io Therapeutics (United States)), Brian Doyon(Tango Therapeutics (United States)), Matthew R. Tonini(Tango Therapeutics (United States)), Candace L. Haddox(Rutgers, The State University of New Jersey)
Cancer Research
April 21, 2025
Cited by 0


Related Papers